Literature DB >> 22104575

Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients.

N L Ainsworth1, A Marshall, H Hatcher, L Whitehead, G A Whitfield, H M Earl.   

Abstract

BACKGROUND: The aim was to evaluate the accuracy of Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae as a substitute for the gold standard measure of glomerular filtration rate (GFR) using chromium 51 EDTA. PATIENTS AND METHODS: Retrospective analysis of GFR measurements in oncology patients from a University Teaching Hospital over 3 years was carried out. Bias and precision of estimates of GFR were compared with measured GFR.
RESULTS: Six hundred and sixty patients with measured GFR (median 90 ml/min, range 23-179 ml/min) were identified. Cockcroft-Gault produced the smallest bias (median percentage error -1.4%) and highest precision (median absolute percentage error 14.0%) and was the most accurate for carboplatin dosing. For patients>30% over their ideal body weight (IBW), using IBW+30% in the Cockcroft-Gault formula was more precise than using actual body weight or IBW. The Wright formula was most accurate for patients aged 70+years and patients with a body mass index (BMI)≥30 but overestimated GFR when GFR<50 ml/min.
CONCLUSIONS: When measured GFR is unavailable, we advise estimating GFR using the Cockcroft-Gault formula and using IBW+30% for patients weighing>30% over their IBW. If the GFR is ≥50 ml/min and the patient is >70 years and/or BMI≥30, the Wright formula gives the best estimate of GFR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104575     DOI: 10.1093/annonc/mdr539

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  14 in total

1.  Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Authors:  Heinz Ludwig; Elisabeth Rauch; Thomas Kuehr; Zdeněk Adam; Adalbert Weißmann; Hedwig Kasparu; Eva-Maria Autzinger; Daniel Heintel; Richard Greil; Wolfram Poenisch; Ercan Müldür; Niklas Zojer
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

2.  Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies.

Authors:  Pierre Delanaye; Fabrice Guerber; André Scheen; Timothy Ellam; Antoine Bouquegneau; Dorra Guergour; Christophe Mariat; Hans Pottel
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

3.  Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies.

Authors:  Jan H Beumer; Fei Ding; Hussein Tawbi; Yan Lin; Diana Viluh; Indrani Chatterjee; Matthew Rinker; Selina L Chow; S Percy Ivy
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

4.  Association between renal function and chemotherapy-related toxicity in older adults with cancer.

Authors:  Lindsay L Peterson; Arti Hurria; Tao Feng; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Ilya Glezerman; Vani Katheria; Laura Zavala; David D Smith; Can-Lan Sun; William P Tew
Journal:  J Geriatr Oncol       Date:  2016-11-14       Impact factor: 3.599

Review 5.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

6.  Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study.

Authors:  Arlene O Siefker-Radtke; Matthew T Campbell; Mark F Munsell; Deborah R Harris; Robert L Carolla; Lance C Pagliaro
Journal:  Urology       Date:  2015-12-23       Impact factor: 2.649

Review 7.  GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer.

Authors:  Blaithin A McMahon; Mitchell H Rosner
Journal:  Kidney360       Date:  2020-01-13

8.  Improving Carboplatin Dosing Based on Estimated GFR.

Authors:  Jan H Beumer; Lesley A Inker; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2017-12-06       Impact factor: 8.860

9.  Overestimation of carboplatin doses is avoided by radionuclide GFR measurement.

Authors:  A J Craig; J Samol; S D Heenan; A G Irwin; A Britten
Journal:  Br J Cancer       Date:  2012-08-30       Impact factor: 7.640

Review 10.  Individualizing pharmacotherapy in patients with renal impairment: the validity of the Modification of Diet in Renal Disease formula in specific patient populations with a glomerular filtration rate below 60 ml/min. A systematic review.

Authors:  Willemijn L Eppenga; Cornelis Kramers; Hieronymus J Derijks; Michel Wensing; Jack F M Wetzels; Peter A G M De Smet
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.